3
by Clark, Michelle, Featherstone, Robin
Published 2019
CADTH
.... The production of methamphetamine is dangerous and produces large volumes of toxic chemical waste. In 2006...

4
by Clark, Michelle, Featherstone, Robin
Published 2019
CADTH
.... The production of methamphetamine is dangerous and produces large volumes of toxic chemical waste. In 2006...

5
by Pohar, Ron, McCormack, Suzanne
Published 2019
Canadian Agency for Drugs and Technologies in Health
...The Eczema Society of Canada has a Seal of Acceptance program "where products are reviewed to earn...

6
by Pohar, Ron, McCormack, Suzanne
Published 2019
Canadian Agency for Drugs and Technologies in Health
...The Eczema Society of Canada has a Seal of Acceptance program "where products are reviewed to earn...

7
by La Fleur, Philip, Jones, Sarah
Published 2017
Canadian Agency for Drugs and Technologies in Health
... products. These products use antimicrobial agents such as triclosan, chlorhexidine, iodophors or quaternary...

8
by La Fleur, Philip, Jones, Sarah
Published 2017
Canadian Agency for Drugs and Technologies in Health
... products. These products use antimicrobial agents such as triclosan, chlorhexidine, iodophors or quaternary...

9
Published 2015
Canadian Agency for Drugs and Technologies in Health
... associated side effects including drowsiness, dizziness and dry mouth; according to the product monograph...

10
Published 2016
Canadian Agency for Drugs and Technologies in Health

11
by Richardson, Robin, Adcock, Lorna
Published 2018
CADTH
..., administration of blood product) in pre-hospital settings, and to examine clinical guidelines regarding the use...

12
by Richardson, Robin, Adcock, Lorna
Published 2018
CADTH
..., administration of blood product) in pre-hospital settings, and to examine clinical guidelines regarding the use...

13
Published 2015
Canadian Agency for Drugs and Technologies in Health
... associated side effects including drowsiness, dizziness and dry mouth; according to the product monograph...

14
Published 2015
CADTH Rapid Response Service
... to innovator INX, which could lead to patients being switched between products. The purpose of this report...

15
Published 2015
CADTH Rapid Response Service
... to innovator INX, which could lead to patients being switched between products. The purpose of this report...

16
Published 2016
Canadian Agency for Drugs and Technologies in Health

17
Published 2016
Canadian Agency for Drugs and Technologies in Health

18
by Marchand, Dave K., Young, Calvin, Loshak, Hannah
Published 2019
CADTH
... or combination product of buprenorphine with naloxone (BUP-NAL) formulations for the treatment of OUD....

19
by Peprah, Kwakye, McCormack, Suzanne
Published 2019
CADTH
... microvascular leakage, and lessen mucus production. Although benefit of its use in CF has not been proven, ICS...

20
by Peprah, Kwakye, McCormack, Suzanne
Published 2019
CADTH
... microvascular leakage, and lessen mucus production. Although benefit of its use in CF has not been proven, ICS...